Acute urinary morbidity after a permanent 125I implantation for localized prostate cancer

Saiji Ohga, Katsumasa Nakamura, Yoshiyuki Shioyama, Katsunori Tatsugami, Tomonari Sasaki, Takeshi Nonoshita, Tadamasa Yoshitake, Kaori Asai, Hideki Hirata, Seiji Naito, Hiroshi Honda

研究成果: Contribution to journalArticle

4 引用 (Scopus)

抜粋

We evaluated the predictive factors of acute urinary morbidity (AUM) after prostate brachytherapy. From November 2005 to January 2007, 62 patients with localized prostate cancer were treated using brachytherapy. The 125Iodine (125I) seed-delivering method was a modified peripheral pattern. The prescribed dose was 144 Gy. Urinary morbidity was scored at 3 months after implantation. The clinical and treatment parameters were analysed for correlation with AUM. In particular, in this study, Du90 (the minimal dose received by 90% of the urethra), Dup90 (the minimal dose received by 90% of the proximal half of the urethra on the bladder side) and Dud90 (the minimal dose received by 90% of the distal half of the urethra on the penile side) were analysed. We found that 43 patients (69.4%) experienced acute urinary symptoms at 3 months after implantation. Of them, 40 patients had Grade 1 AUM, one patient had Grade 2 pain, and two patients had Grade 2 urinary frequency. None of the patients had ≥Grade 3. Univariate and multivariate analysis revealed that Du90 and Dup90 were significantly correlated with AUM. In this study, Du90 and Dup90 were the most significant predictors of AUM after prostate brachytherapy.

元の言語英語
ページ(範囲)1178-1183
ページ数6
ジャーナルJournal of radiation research
55
発行部数6
DOI
出版物ステータス出版済み - 11 1 2014

All Science Journal Classification (ASJC) codes

  • Radiation
  • Radiology Nuclear Medicine and imaging
  • Health, Toxicology and Mutagenesis

フィンガープリント Acute urinary morbidity after a permanent <sup>125</sup>I implantation for localized prostate cancer' の研究トピックを掘り下げます。これらはともに一意のフィンガープリントを構成します。

  • これを引用